ReCor Medical
ReCor Medical has developed a unique therapeutic non-focused ultrasound system for performing renal denervation in patients with resistant hypertension. The PARADISE™ technology (Percutaneous Renal Denervation System) includes a 6 French-compatible catheter with a cylindrical transducer that emits ultrasound energy circumferentially, allowing for a more efficient renal denervation procedure.
Sector
Medical Devices
Strategy
Capital
Status
Exit
Website
www.recormedical.com
Related News
Recor Medical and Otsuka Medical Devices announce positive vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the treatment of hypertension
ReCor Medical and Otsuka Medical Devices announce primary endpoint met in the RADIANCE II U.S. pivotal trial of the Paradise™ System for the treatment of hypertension
Sofinnova Partners Announces the Sale of ReCor Medical to Otsuka Holdings
ReCor Medical Announces Collaboration and Investment with Otsuka Holdings for Asian Commercialization and Clinical Studies in the US and Europe
ReCor Medical Announces Initial Enrollments in the RADIANCE-HTN Hypertension Clinical Trial
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.